Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

Altimmune (NASDAQ: ALT) announced that its management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference.

Rhea-AI Summary

Altimmune (NASDAQ: ALT) announced that its management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference.

The session is scheduled for Wednesday, December 3, 2025 at 2:30 p.m. ET and will be available via webcast. Investors can access the webcast through the Events section of Altimmune's website.

Argus Nov 26 session

+0.58% close to close Open Argus

Details

News Market Reaction – ALT

On Nov 26, the day this news came out, ALT closed 0.58% above the previous close.

Data tracked by StockTitan Argus for the Nov 26 session.

Key Figures

Conference edition: 37th Annual Conference date: December 3, 2025 Conference time: 2:30 p.m. ET

Conference edition

37th Annual

Piper Sandler Healthcare Conference

Conference date

December 3, 2025

Scheduled fireside chat timing

Conference time

2:30 p.m. ET

Scheduled start of Altimmune session

Historical Context

5 past events · Latest: Dec 01

5 events

1. Dec 01

   CEO transition

   24h Move

   -6.3%

   Leadership change with CEO succession and timeline for outgoing CEO.

2. Nov 26

   Investor conference

   24h Move

   +0.6%

   Announcement of participation in Piper Sandler healthcare conference webcast.

3. Nov 11

   Clinical data update

   24h Move

   +0.5%

   Publication and presentation of positive 24-week IMPACT Phase 2b MASH data.

4. Nov 07

   AI fibrosis analysis

   24h Move

   +4.3%

   AI-based analysis showing significant fibrosis reductions vs placebo in MASH.

5. Nov 06

   Earnings and updates

   24h Move

   +5.1%

   Q3 2025 financials, strong cash balance, loan amendment, and clinical milestones.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cardiometabolic, peptide-based therapeutics

2 terms

cardiometabolic medical

"developing novel peptide-based therapeutics for liver and cardiometabolic diseases"

Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.

peptide-based therapeutics medical

"a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics"

Peptide-based therapeutics are drugs made from short chains of amino acids—think of them as tiny, targeted protein fragments that can act like precision tools to trigger, block or mimic natural processes in the body (imagine a short string of beads fitting into a specific lock). Investors care because these therapies can offer high specificity, potentially faster development and clear clinical targets, but they also carry manufacturing, patent and regulatory risks that affect commercial value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate in a fireside chat at the Piper Sandler 37^th Annual Healthcare Conference. Details are as follows:

Conference: Piper Sandler 37^th Annual Healthcare Conference
Date/Time: Wednesday, December 3, 2025 at 2:30 p.m. ET

The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune

Altimmune is a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a glucagon/GLP-1 dual receptor agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X

Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com

Media Contact:
Savannah Valade
Real Chemistry
altimmune@realchemistry.com

This press release was published by a CLEAR® Verified individual.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Altimmune (ALT) present at the Piper Sandler 37th Annual Healthcare Conference?

Altimmune will present on Wednesday, December 3, 2025 at 2:30 p.m. ET.

How can investors watch Altimmune (ALT) fireside chat on December 3, 2025?

The session will be webcast and can be accessed via the Events section of Altimmune's website.

What topics will Altimmune (ALT) management cover at the Piper Sandler conference?

Management will participate in a fireside chat to discuss recent developments and company outlook; the company did not list specific topics.

Where is the Piper Sandler 37th Annual Healthcare Conference presentation available after the live stream for Altimmune (ALT)?

Recordings are typically posted in the company's Events section; check Altimmune's website after the event.

Who from Altimmune (ALT) will attend the Piper Sandler conference?

The announcement states members of Altimmune's management team will participate; no individual names were provided.

Is there a cost to view Altimmune's (ALT) webcast at the Piper Sandler conference?

The company indicated the session will be webcast via its website; no cost or registration details were provided in the announcement.